Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Gains from Sales and Divestitures: 2020-2025

Historic Gains from Sales and Divestitures for Adma Biologics (ADMA) over the last 5 years, with Sep 2025 value amounting to $1.8 million.

  • Adma Biologics' Gains from Sales and Divestitures rose 8.15% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 8.15%. This contributed to the annual value of $1.9 million for FY2024, which is 57.28% up from last year.
  • Latest data reveals that Adma Biologics reported Gains from Sales and Divestitures of $1.8 million as of Q3 2025, which was up 13.54% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Gains from Sales and Divestitures registered a high of $2.7 million during Q4 2022, and its lowest value of $87,750 during Q2 2021.
  • Over the past 3 years, Adma Biologics' median Gains from Sales and Divestitures value was $1.4 million (recorded in 2024), while the average stood at $1.3 million.
  • Per our database at Business Quant, Adma Biologics' Gains from Sales and Divestitures surged by 2,840.61% in 2022 and then plummeted by 56.02% in 2023.
  • Quarterly analysis of 5 years shows Adma Biologics' Gains from Sales and Divestitures stood at $92,750 in 2021, then skyrocketed by 2,840.61% to $2.7 million in 2022, then slumped by 56.02% to $1.2 million in 2023, then soared by 57.28% to $1.9 million in 2024, then climbed by 8.15% to $1.8 million in 2025.
  • Its Gains from Sales and Divestitures stands at $1.8 million for Q3 2025, versus $1.6 million for Q2 2025 and $1.5 million for Q1 2025.